



Integra LifeSciences to Present At Two Conferences in May

PLAINSBORO, N.J., Apr 30, 2009 (GlobeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it is scheduled to present at two conferences in May.

On Wednesday, May 13, 2009 at 8:40 AM, Stuart Essig, Integra's President and Chief Executive Officer, will present at the Bank of America and Merrill Lynch 2009 Health Care Conference at The Palace Hotel in New York City, New York. A webcast will be available for this conference via a link at our website at www.integra-LS.com in the Investor Relations section. A replay of the webcast will be available for two weeks following the live event.

On Monday, May 18, 2009, at 8:00 AM, John B. Henneman III, Integra's Executive Vice President, Finance and Administration, and Chief Financial Officer, will present at the Eighth Annual JMP Securities Research Conference at The Ritz-Carlton in San Francisco, CA. This presentation will not be webcast.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Our products, used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, are used to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at (<http://www.Integra-LS.com>).

Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2008 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

IART-G

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings
Corporation

John B. Henneman, III, Executive Vice President
Finance and Administration
and Chief Financial Officer

(609) 275-0500

jhenneman@Integra-LS.com

Angela Steinway, Manager, Investor Relations

(609) 936-2268

angela.steinway@integra-LS.com

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX